Liraglutide Attenuates Diabetic Cardiomyopathy via the ILK/PI3K/AKT/PTEN Signaling Pathway in Rats with Streptozotocin-Induced Type 2 Diabetes Mellitus

Alobaid, Shatha M.; Alshahrani, Rahaf M.; Alonazi, Asma S.; Alrasheed, Nawal M.; Alamin, Maha A.; Alshammari, Tahani K.; Bin Dayel, Anfal F.; Elnagar, Doaa M.; Alotaibi, Rana R.; Almuthnabi, Lama A.; Almasud, Dalia H.; Al-Ammar, Shahad E.; Almadhi, Shahad O.; Almalke, Reema A.; Aldamri, Nouf T.; Alghibiwi, Hanan K.; Alkhelb, Dalal A.; Alrasheed, Nouf M.

doi:10.3390/ph17030374

Liraglutide Attenuates Diabetic Cardiomyopathy via the ILK/PI3K/AKT/PTEN Signaling Pathway in Rats with Streptozotocin-Induced Type 2 Diabetes Mellitus

One of the possible candidates for the treatment of diabetic cardiomyopathy is liraglutide, a glucagon-like peptide-1 receptor (GLP1R) agonist. In this study, the impacts of liraglutide on the integrin-linked kinase (ILK)-related PI3K/AKT axis in rats with type 2 diabetes induced via streptozotoc…